

**Supplementary Table 3. Third-line treatment strategies**

Third-line treatment		1980-1989	1990-1999	2000-2009	2010-2017	Total
No treatment	n	0	1	4	0	5
	%	0%	1%	6%	0%	3%
R-CHOP/R-CVP	n	1	7	6	0	14
	%	3%	9%	10%	0%	7%
Single-agent rituximab	n	2	6	8	1	17
	%	6%	7%	13%	7%	9%
Benda/Fluda-based (+/- R)	n	1	15	9	2	27
	%	3%	18%	15%	13%	14%
Other chemo regimens	n	18	30	16	12	76
	%	53%	37%	26%	80%	39%
Chlorambucil and other agents	n	8	1	0	0	9
	%	24%	1%	0%	0%	5%
ASCT	n	4	18	11	0	33
	%	12%	22%	18%	0%	17%
Allo-SCT	n	0	4	8	0	12
	%	0%	5%	13%	0%	6%

CVP, cyclophosphamide, vincristine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; Benda, bendamustine; Fluda, fludarabine; chemo, chemotherapy; ASCT, autologous stem cell transplantation; Allo-SCT, allogeneic stem cell transplantation.